In this episode of The Midweek Takeaway, Phil Carroll and Kevin Hornsby speak with Anthony Tennyson, CEO of Solvonis Therapeutics (LSE: SVNS), about the company’s strengthened leadership following the appointment of Paul Carter, former Gilead CCO, and its progress across key CNS programmes. Anthony outlines Solvonis’ licensing-first, capital-efficient model and updates on SVN-001 for alcohol use disorder, SVN-002 for the US market, and SVN-SDN-14 targeting PTSD — reflecting Solvonis’ mission to advance next-generation treatments for addiction and mental health.

This podcast may contain paid promotions, including but not limited to sponsorships, endorsements, or affiliate partnerships. The information, investment views, and recommendations provided are for general informational purposes only and should not be construed as a solicitation to buy or sell any financial products related to the companies discussed. Any opinions or comments are made to the best of the knowledge and belief of the commentators; however, no responsibility is accepted for actions based on such opinions or comments. The commentators may or may not hold investments in the companies under discussion. Listeners are encouraged to perform their own research and consult with a licensed professional before making any financial decisions based on the content of this podcast.